- GlobeNewswire•yesterdayTetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI
WATERTOWN, Mass., Jan. 17, 2017-- Tetraphase Pharmaceuticals, Inc. today announced dosing of the first patient in IGNITE3, the Company’ s phase 3 clinical trial evaluating the efficacy and safety of once-daily ...
- American City Business Journals•14 days ago
Deloitte won more auditing work from Massachusetts businesses going public last year than any other accounting firm, landing jobs with a third of the companies that underwent initial public offerings statewide. The firm’s Boston office audited three biotech companies — Syndax Pharmaceuticals (SNDX), Intellia Therapeutics (NTLA) and Ra Pharmaceuticals (RARX) — and the tech company Acacia Communications (ACIA) in the leadup to their 2016 IPOs. Massachusetts was home to 12 IPOs last year, according to Renaissance Capital, a manager of IPO-focused exchange-traded funds.
- GlobeNewswire•last month
–Company to Submit MAA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections to the EMA in Second Half of 2017–. –Phase 3 IGNITE3 Study in Complicated Urinary Tract Infections to ...
TTPH : Summary for Tetraphase Pharmaceuticals, Inc - Yahoo Finance
Tetraphase Pharmaceuticals, Inc. (TTPH)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||4.15 x 2300|
|Ask||4.18 x 400|
|Day's Range||4.16 - 4.26|
|52 Week Range||3.11 - 6.28|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.09|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|